Pharmala Biotech Holdings Inc.
MDMA.CNCNQHealthcare● Active
$0.14
+$0.01(+3.70%)
Market Cap$15244210
P/E Ratio—
52W High$0.195
52W Low$0.085
Pharmala Biotech Holdings Inc. (MDMA.CN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDMA.CN · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 30, 2023EPS Actual
$0.00
Revenue
$0.00B
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 30, 2023
After Market Close
MDMA.CN reports quarterly as a CNQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 30, 2023 | — | $0.00 | — | $0.00B | — | — |
| — Q2 FY2023 | May 31, 2023 | — | -$0.00 | — | — | — | — |
| — Q1 FY2023 | Feb 28, 2023 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2022 | Nov 30, 2022 | — | -$0.00 | — | — | — | — |
| — Q3 FY2022 | Aug 31, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q2 FY2022 | May 31, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q1 FY2022 | Feb 28, 2022 | — | -$0.00 | — | — | — | — |
| — Q4 FY2021 | Nov 30, 2021 | — | -$0.00 | — | — | — | — |
Q4 FY2023
Nov 30, 2023
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
May 31, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Feb 28, 2023
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Nov 30, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 31, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2022
May 31, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2022
Feb 28, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Nov 30, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for MDMA.CN.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 30, 2023 | — | $0.10 | $0.10 | +0.00% |
| — Q2 FY2023 | May 31, 2023 | — | $0.27 | $0.34 | +24.07% |
| — Q1 FY2023 | Feb 28, 2023 | — | $0.13 | $0.14 | +3.85% |
| — Q4 FY2022 | Nov 30, 2022 | — | $0.03 | $0.03 | -16.67% |
| — Q3 FY2022 | Aug 31, 2022 | — | $0.06 | $0.05 | -16.67% |
| — Q2 FY2022 | May 31, 2022 | — | $0.03 | $0.03 | +0.00% |
| — Q1 FY2022 | Feb 28, 2022 | — | $0.06 | $0.06 | +9.09% |
| — Q4 FY2021 | Nov 30, 2021 | — | No price data | $0.08 | — |
Q4 FY2023+0.00%
Report Date
Nov 30, 2023
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q2 FY2023+24.07%
Report Date
May 31, 2023
EPS Beat/Miss
—
Price Before
$0.27
Price After
$0.34
Q1 FY2023+3.85%
Report Date
Feb 28, 2023
EPS Beat/Miss
—
Price Before
$0.13
Price After
$0.14
Q4 FY2022-16.67%
Report Date
Nov 30, 2022
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q3 FY2022-16.67%
Report Date
Aug 31, 2022
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.05
Q2 FY2022+0.00%
Report Date
May 31, 2022
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q1 FY2022+9.09%
Report Date
Feb 28, 2022
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q4 FY2021—
Report Date
Nov 30, 2021
EPS Beat/Miss
—
Price Before
—
Price After
$0.08
Beat Rate0 / 8 quarters
Largest Move+24.07% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDMA.CN ends December
Pharmala Biotech Holdings Inc. (MDMA.CN) most recently reported earnings on November 30, 2023 for Q4 FY2023, posting EPS of $0.00 (in line with the analyst consensus of —).
Each quarter, investors track MDMA.CN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDMA.CN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDMA.CN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDMA.CN earnings · 4 questionsPharmala Biotech Holdings Inc.'s next earnings report is expected around TBD. MDMA.CN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDMA.CN historically reports after market close (AMC).
MDMA.CN earnings datewhen is MDMA.CN earningsMDMA.CN next earnings datewhen does MDMA.CN report earningsMDMA.CN earnings calendar
▸ Source: FMP · Pharmala Biotech Holdings Inc. SEC filings · US GAAP · Pharmala Biotech Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026